Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
O75916
UPID:
RGS9_HUMAN
Alternative names:
-
Alternative UPACC:
O75916; A8K3C0; O75573; Q696R2; Q8TD64; Q8TD65; Q9HC32; Q9HC33
Background:
Regulator of G-protein signaling 9 (RGS9) plays a pivotal role in the visual system by accelerating the deactivation of G proteins, thereby facilitating the rapid recovery of photoreceptors to their pre-activated state. This process is crucial for the ability of eyes to adjust to varying light conditions.
Therapeutic significance:
RGS9 is linked to Prolonged electroretinal response suppression 1 (PERRS1), a disorder that affects vision adaptation in changing luminance. Understanding RGS9's function could lead to novel treatments for PERRS1, enhancing quality of life for those affected.